ECSP055575A - Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel. - Google Patents

Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.

Info

Publication number
ECSP055575A
ECSP055575A EC2005005575A ECSP055575A ECSP055575A EC SP055575 A ECSP055575 A EC SP055575A EC 2005005575 A EC2005005575 A EC 2005005575A EC SP055575 A ECSP055575 A EC SP055575A EC SP055575 A ECSP055575 A EC SP055575A
Authority
EC
Ecuador
Prior art keywords
treatment
skin diseases
thio
oxindol derivatives
oxindol
Prior art date
Application number
EC2005005575A
Other languages
English (en)
Inventor
Andrew Fensome
Diane Deborah Harrison
Richarg Craing Winneker
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP055575A publication Critical patent/ECSP055575A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth

Abstract

La presente invención proporciona métodos para el tratamiento de enfermedades de la piel, el cual incluye la administración a un mamífero de una composición que contiene un compuesto de fórmula I, o tautómeros del mismo, en un régimen donde la fórmula I es como se muestra y donde R1-R5 y Q1 son definidos como se describe aquí. Específicamente se describen métodos para el tratamiento del acné, el hirsutismo y una composición para acondicionar la piel.
EC2005005575A 2002-06-25 2005-01-25 Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel. ECSP055575A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39191302P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
ECSP055575A true ECSP055575A (es) 2005-04-18

Family

ID=30000776

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005575A ECSP055575A (es) 2002-06-25 2005-01-25 Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.

Country Status (17)

Country Link
US (1) US7115649B2 (es)
EP (1) EP1515680A4 (es)
JP (1) JP2005535625A (es)
KR (1) KR20050012831A (es)
CN (1) CN1662206A (es)
AR (1) AR040338A1 (es)
AU (1) AU2003258952A1 (es)
BR (1) BR0312092A (es)
CA (1) CA2489810A1 (es)
EC (1) ECSP055575A (es)
IL (1) IL165394A0 (es)
MX (1) MXPA04012418A (es)
NO (1) NO20045215L (es)
RU (1) RU2005101624A (es)
TW (1) TW200401637A (es)
WO (1) WO2004000227A2 (es)
ZA (1) ZA200410401B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CA2489813A1 (en) * 2002-06-25 2003-12-31 Wyeth Use of thio-oxindole derivatives in treatment of hormone-related conditions
ATE413398T1 (de) * 2004-04-08 2008-11-15 Wyeth Corp Thioamidderivate als progesteronrezeptormodulatoren
WO2005100347A1 (en) * 2004-04-08 2005-10-27 Wyeth Methods for minimizing thioamide impurities
US7514466B2 (en) * 2004-04-27 2009-04-07 Wyeth Purification of progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
CL2007002950A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Uso de compuestos derivados de espiro-oxindol en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
CN101680026A (zh) * 2007-01-12 2010-03-24 康乃尔研究基金会有限公司 作为真核病原体感染治疗的新型靶的腺苷酰环化酶
RU2011119626A (ru) 2008-10-17 2012-11-27 Ксенон Фармасьютикалз Инк. Спирооксиндольные соединения и их применение в качестве терапевтичеких средств
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
RU2015103694A (ru) 2009-10-14 2015-06-27 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
KR101278271B1 (ko) * 2011-08-02 2013-06-25 충남대학교산학협력단 인돌린-2-티온 유사체를 함유한 미백용 조성물
WO2014025942A1 (en) 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169198A (en) * 1875-10-26 Improvement in treating quicksilver-ore
US92711A (en) * 1869-07-20 e d w a r d s
DE3380923D1 (de) * 1983-07-29 1990-01-11 Univ Duke Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
ES2258342T3 (es) * 1998-10-23 2006-08-16 Aventis Pharma S.A. Preparaciones para aplicacion topica de sustancias que tienen efecto antiandrogenico.
KR20010108063A (ko) 1998-12-31 2001-12-07 수젠, 인크. 단백질 인산화 효소의 조절 및 암의 화학적 치료를 위한3-헤테로아릴리데닐-2-인돌리논 화합물
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
DE60036628T2 (de) 1999-08-26 2008-07-03 Automotive Systems Laboratory Inc., Farmington Hills Magnetischer sensor
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7119207B2 (en) 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
AP2002002647A0 (en) 2000-04-10 2002-12-31 Pfizer Prod Inc Benzoamide piperidine compounds as substance p antagonists
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US7375380B2 (en) * 2004-07-12 2008-05-20 Rohm Co., Ltd. Semiconductor light emitting device

Also Published As

Publication number Publication date
MXPA04012418A (es) 2005-04-19
KR20050012831A (ko) 2005-02-02
TW200401637A (en) 2004-02-01
AU2003258952A1 (en) 2004-01-06
EP1515680A4 (en) 2005-09-21
US7115649B2 (en) 2006-10-03
CA2489810A1 (en) 2003-12-31
CN1662206A (zh) 2005-08-31
ZA200410401B (en) 2006-05-31
WO2004000227A2 (en) 2003-12-31
WO2004000227A3 (en) 2004-04-08
AR040338A1 (es) 2005-03-30
EP1515680A2 (en) 2005-03-23
RU2005101624A (ru) 2005-06-27
JP2005535625A (ja) 2005-11-24
US20040006122A1 (en) 2004-01-08
NO20045215L (no) 2005-03-17
IL165394A0 (en) 2006-01-15
BR0312092A (pt) 2005-03-22

Similar Documents

Publication Publication Date Title
ECSP055575A (es) Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.
ECSP055572A (es) Derivados ciclotiocarbamativos como moduladores pr y el uso de los mismos en el tratamiento de enfermedades de la piel.
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
CR10874A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3 metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro benzonitrilo y metodos para el uso de los mismos
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
TW200637614A (en) Bendamustine pharmaceutical compositions
PA8680701A1 (es) Derivados de oxindol
CR9987A (es) Compuestos de lactama y métodos de uso de los mismos
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY33616A (es) Compuestos con estructura de imidazotriazinona
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
AR052322A1 (es) Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica
UY29417A1 (es) Agentes endoparasiticidas
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler